20/02/2025 - Press release
Researchers identify predictive markers of response to immunotherapy treatment in a study involving data from over 700 patients across six different cohorts, published in Nature Communications. The study has significant relevance, impacting the management of bladder cancer patients. Machine learning tools enabled the identification of key variables for the success of immunotherapy treatment. This innovative methodology has allowed researchers to pinpoint which tumor subtypes respond best to immunotherapy.
Més informació "Massive Data Analysis Advances the Understanding of How Immunotherapy Works"
13/02/2025 - Press release
Specifically, for every year of increase in the difference between chronological age (based on birthdate) and biological age (determined by lifestyle habits and exposure to external factors), the risk of developing cancer after any type of stroke increases by 6.6%. This is the first time a clear relationship has been established between biological age and cancer risk in these patients. Biological age can be modified by changing lifestyle habits, which could reduce the chances of developing cancer after recovering from a stroke.
06/02/2025 - Press release
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to treatment. The device, which has already been successfully tested on breast cancer samples, could be key to developing new treatments and determining the most appropriate therapy for each patient in a personalized way. The work, published in Nature Communications, is the result of a collaboration between the Institute for Bioengineering of Catalonia and the Research Institute of the Hospital del Mar.
23/01/2025 - Press release
According to a multicenter study published in the Journal of Hospital Infection, involving twelve hospitals across the country. Patients hospitalized due to healthcare-associated urinary tract infections caused by antibiotic-resistant bacteria require longer hospital stays-an average of three additional days compared to cases caused by bacteria that respond to treatment. The authors warn about the high number of cases caused by resistant bacteria, emphasizing the need to take stricter precautions in the use of antibiotics.
09/01/2025 - Press release
A multicenter study led by the Hospital del Mar Research Institute identifies five circulating microRNAs in the blood as potential markers for recovery in patients who have suffered a stroke. These small RNA molecules play a significant role in modulating the activity of genes linked to prognosis in ischemic stroke cases. The ability to regulate their activity could pave the way for new treatments to improve outcomes for individuals affected by this condition.
17/12/2024 - Press release
Phase 1/2 of the clinical trial shows that the administration of the AEF0217 molecule developed by the biotech Aelis Farma, is safe and can improve key skills such as communication, social interactions and daily living for people with Down syndrome These results reinforce the start of the phase 2 clinical trial, through an international multicenter study with people with Down syndrome, focused on the dose necessary to achieve the treatment goal
11/12/2024 - Press release
Consuming 20-30% of daily energy intake in the morning influences key cardiovascular risk factors. People who consume the right amount of energy in the morning have 2-3.5% lower body mass index, less abdominal obesity (2-4% smaller waist circumference), 9-18% lower triglycerides, and 4-8.5% higher HDL cholesterol (the good cholesterol). Additionally, having a high-quality breakfast with a balanced intake of proteins, high-value fats, fiber, calcium, and iron is associated with a 1.5% smaller waist circumference, 4% lower triglycerides, and 3% higher HDL cholesterol. The study tracked nearly 400 participants of the PREDIMED-Plus study over three years, which analyzes the effects of the Mediterranean diet on participants' health.
Més informació "Having a good breakfast reduces cardiovascular risk"
02/12/2024 - Press release
A study by the Hospital del Mar Research Institute, in collaboration with the University of Vic-Central University of Catalonia (UVic-UCC), published in the Revista Española de Cardiología, validates the effectiveness of this type of initiative. Implementing out-of-hospital care programs reduces the fatality rate of heart attacks by 35% and long-term mortality by 27%.
19/11/2024 - Press release
A scientific article by the PASOS consortium, led by the Gasol Foundation and the Hospital del Mar Research Institute, confirms that nearly 60% of children with overweight present abdominal obesity. 56.1% of the population aged 8 to 16 with overweight (based on BMI) has an excess of fat around the waist, a percentage that 20 years ago stood at 40%. Abdominal obesity is associated with visceral fat, a condition defining cardiometabolic risk, which already affects more than 1 million children aged 8 to 16 in Spain. The PASOS study by the Gasol Foundation continues to contribute to scientific evidence and understanding the issue of childhood obesity.
18/11/2024 - Press release
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment. This dual mechanism of action has demonstrated safety and achieved complete and durable antitumor responses in patient-derived models of HER2+ p95HER2-expressing solid tumors. Published in Nature Communications, results of this VHIO-led study have provided the rationale for the application of a phase 1 first-in-human clinical trial, currently in the approval process, to assess this novel therapeutic strategy in patients with HER2-driven solid tumors.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
